Wednesday, 4 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Merger & Restructuring

Nectar Lifesciences Merger & Restructuring

Nectar Lifesciences extended the expected completion date for the slump sale of its Empty Hard Gelatin Capsule business to Capnest Health Care to December 31, 2026.

Source

BSE filing, NSE: NECLIFE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Nectar Lifesciences Ltd: key numbers

Share price
₹10.15
Market cap
₹227.6 Cr
Revenue (annual)
₹0.00 Cr
Net profit (annual)
₹-292.9 Cr
P/E (TTM)
-0.9×Sector 41.3×
Promoter holding
51.84%+0.00% QoQ
FII holding
0.50%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Nectar Lifesciences Ltd

All →

Other merger & restructuring announcements

All →